StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)

Close on Nov 18, 2026Market cap $226.76MP/E –Yield –

Vanda Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Vanda Pharmaceuticals's pe ratio was 119.0× on Apr 30, 2024, against 55.8× a year earlier. Over the last 5 years it ranged from 4.6× to 119.0×, with a median of 28.6×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Apr 30, 2024119.0×+98.9
2023Dec 29, 202320.1×−41.5
2022Dec 30, 202261.6×+35.9
2021Dec 31, 202125.7×−10.8
2020Dec 31, 202036.5×+29.1
2019Dec 31, 20197.4×−101.5
2018Dec 31, 2018108.9×+101.7
2016Jan 29, 20167.2×−0.7
2015Dec 31, 20157.9×−33.6
2011Oct 31, 201141.5×–

More Vanda Pharmaceuticals figures

See a number that looks wrong?